| ORIGINAL ARTICLE |
|
| Year : 2021 | Volume
: 12
| Issue : 1 | Page : 9-13 |
|
|
A retrospective study to assess the risk of bladder cancer in type-2 diabetic patients treated with pioglitazone
Prabhat Agrawal, Apoorva Jain, Ashish Gautam, Ashwini Kumar Nigam, Nikhil Pursnani, Maaz Farooqui
Department of Medicine, S. N. Medical College, Agra, Uttar Pradesh, India
Correspondence Address:
Dr. Apoorva Jain
Department of Medicine, S. N. Medical College, Agra, Uttar Pradesh
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/picr.PICR_192_18
|
|
|
Introduction: Pioglitazone has been a cornerstone of oral hypoglycemic therapy. Concerns have been raised about its association with urinary bladder cancer. Considering the wide usage of this drug, concrete and multiple population-based studies are needed to establish the safety of this drug. The present retrospective study is aimed to assess the association of pioglitazone with urinary bladder cancer.
Materials and Methods: Clinical records of 4170 patients (2085 pioglitazone users and similar number of nonpioglitazone users) attending the diabetes clinic at a tertiary level teaching hospital were accessed, and the patients were subjected to symptom-directed questionnaire, urine examination, and cystoscopy and bladder biopsy (whenever clinically indicated). The risk of bladder cancer was also assessed with respect to cumulative dose and duration of pioglitazone.
Results: We did not observe any increased risk of bladder malignancy with pioglitazone exposure; furthermore, there was no association with cumulative dose and duration of pioglitazone therapy. Pioglitazone was found to be effective and safe in managing glycemic control in diabetic patients. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
